{
    "name": "mometasone topical",
    "comment": "Rx",
    "other_names": [
        "Elocon"
    ],
    "classes": [
        "Corticosteroids",
        "Topical"
    ],
    "source": "https://reference.medscape.com/drug/elocon-mometasone-topical-343513",
    "pregnancy": {
        "common": [
            "Pregnancy Category: C",
            "Lactation: use caution"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "Lactation: use caution"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Safety/efficacy in children use for longer than 3 wk not established; pediatric patients may be more susceptible to systemic toxicity",
                "Do not use with occlusive dressings",
                "Not for acne, rosacea, perioral dermatitis, diaper dermatitis",
                "If concomitant skin infections are present or develop, use appropriate antifungal or antibacterial agent; if favorable response does not occur promptly, therapy should be discontinued until infection has been adequately controlled",
                "If irritation develops, discontinue therapy and institute appropriate therapy; allergic contact dermatitis with corticosteroids is usually diagnosed by observing failure to heal rather than noting a clinical exacerbation; corroborate observation with appropriate diagnostic patch testing",
                "Use of topical corticosteroids may increase risk of posterior subcapsular cataracts and glaucoma; cataracts and glaucoma reported in postmarketing experience with therapy; avoid contact with eyes; advise patients to report any visual symptoms and consider referral to ophthalmologist for evaluation"
            ],
            "specific": [
                {
                    "type": "Endocrine system effects",
                    "description": [
                        "Systemic absorption of topical corticosteroids can produce reversible hypothalamic-pituitary-adrenal (HPA) axis suppression with potential for glucocorticosteroid insufficiency; this may occur during treatment or after withdrawal of treatment",
                        "Manifestations of Cushing's syndrome, hyperglycemia, and glucosuria can be produced in some patients by systemic absorption of topical corticosteroids while on treatment",
                        "Factors that predispose a patient using a topical corticosteroid to HPA axis suppression include use of high potency steroids, large treatment surface areas, prolonged use, use of occlusive dressing, altered skin barrier, liver failure and young age",
                        "Because of potential for systemic absorption, use of topical corticosteroids may require that patients be periodically evaluated for HPA axis suppression; this may be done by using the adrenocorticotropic hormone (ACTH) stimulation test",
                        "If HPA axis suppression documented, attempt to gradually withdraw drug, to reduce frequency of application, or to substitute a less potent corticosteroid; recovery of HPA axis function is generally prompt upon discontinuation of topical corticosteroids; infrequently, signs and symptoms of glucocorticosteroid insufficiency may occur, requiring supplemental systemic corticosteroids",
                        "Pediatric patients may be more susceptible to systemic toxicity from equivalent doses due to their larger skin surface to body mass ratios"
                    ]
                }
            ]
        }
    },
    "interactions": [
        {
            "classification_type": "Contraindicated",
            "interaction_with": "mifepristone",
            "description": {
                "common": "mifepristone, mometasone topical.\nEither increases toxicity of the other by Other (see comment). Contraindicated. \nComment: Mifepristone is contraindicated in patients on long-term corticosteriod treatment due to increase risk of adrenal insufficiency."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "aldesleukin",
            "description": {
                "common": "mometasone topical decreases effects of aldesleukin by unspecified interaction mechanism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ceritinib",
            "description": {
                "common": "mometasone topical decreases effects of ceritinib by Other (see comment). Modify Therapy/Monitor Closely. \nComment: Closely monitor for severe hyperglycemia (serum glucose >250 mg/dL) and treat appropriately. Patients with history of diabetes or glucose intolerance are at increased risk. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "corticorelin",
            "description": {
                "common": "mometasone topical decreases effects of corticorelin by pharmacodynamic antagonism. Use Caution/Monitor. Recent or current corticosteroid therapy may blunt the response to corticorelin, potentially interfering with the corticorelin stimulation test results."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "deferasirox",
            "description": {
                "common": "mometasone topical decreases effects of deferasirox by unspecified interaction mechanism. Use Caution/Monitor. Due to the risk for GI bleeding and irritation/ulceration associated with deferasirox, exercise caution when using with corticosteroids, that can also cause gastrointestinal ulceration and/or bleeding."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "hyaluronidase",
            "description": {
                "common": "mometasone topical decreases effects of hyaluronidase by unspecified interaction mechanism. Modify Therapy/Monitor Closely. Patients receiving larger doses of corticosteriods may not experience the desired clinical response to standard doses of hyaluronidase. Larger doses of hyaluronidase may be required."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "omacetaxine",
            "description": {
                "common": "omacetaxine, mometasone topical.\nEither increases toxicity of the other by Other (see comment). Modify Therapy/Monitor Closely. \nComment: Concomitant use with omacetaxine and mometasone topical may enhance the risk of infections and myelosuppression."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Burning",
            "percent": null
        },
        {
            "name": "Itching",
            "percent": null
        },
        {
            "name": "Pruritus",
            "percent": null
        },
        {
            "name": "Rosacea",
            "percent": null
        },
        {
            "name": "Irritation",
            "percent": null
        },
        {
            "name": "Dryness",
            "percent": null
        },
        {
            "name": "Folliculitis",
            "percent": null
        },
        {
            "name": "Hypertrichosis",
            "percent": null
        },
        {
            "name": "Acneiform eruptions",
            "percent": null
        },
        {
            "name": "Hypopigmentation",
            "percent": null
        },
        {
            "name": "Perioral dermatitis",
            "percent": null
        },
        {
            "name": "Allergic contact dermatitis",
            "percent": null
        },
        {
            "name": "Secondary infection",
            "percent": null
        },
        {
            "name": "Skin atrophy",
            "percent": null
        },
        {
            "name": "Striae",
            "percent": null
        },
        {
            "name": "Miliaria",
            "percent": null
        },
        {
            "name": "Blurred vision",
            "percent": null
        },
        {
            "name": "Cataracts",
            "percent": null
        },
        {
            "name": "Glaucoma",
            "percent": null
        },
        {
            "name": "Increased intraocular pressure",
            "percent": null
        },
        {
            "name": "Central serous chorioretinopathy",
            "percent": null
        }
    ]
}